Market reaction to recent readouts from Compass Pathways and Beckley Psytech/atai in treatment-resistant depression speaks to ...

COMPASS Pathways plc (NASDAQ:CMPS) is among the best get rich quick stocks to buy now. ARK Invest’s ETFs, led by Cathie Wood, ...

Enhanced Virtual Trip platform goes live with improved user experience and first selection of PS2025 session videosConference ...

Compass Pathways’ stock has crashed by nearly 50% despite the company announcing its Phase III trial of psilocybin had met its primary endpoint in a Phase III trial. While the British company is ...

12 out of 14 patients went into remission for three months following a single 25mg dose of COMP360 psilocybin therapy, in an independent investigator-initiated, exploratory open-label study of ...

London, UK, June 28, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to acceler ...

LONDON, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating pat ...

COMP360 appears to be compatible with certain antidepressant medications. That's contrary to some prior assumptions, so it's a pleasant surprise. The therapy's addressable market is probably ...

COMP360 As Psilocybin For The Treatment Of Patients With Treatment Resistant-Depression The first and main clinical program to go over in COMPASS' pipeline, would be its psilocybin drug.

The COMP360 psilocybin session. The patient lies down on a bed in a comfortable room, designed specifically for the session. They receive a dose of investigational COMP360 psilocybin in a capsule.

COMPASS on track to report data in late 2021. London, UK, June 28, 2021-- COMPASS Pathways plc, a mental health care company dedicated to accelerating patient access to evidence-based innovation ...